Table 3.
Outcomes of selected randomized controlled clinical trials in metastatic pancreatic adenocarcinoma
| Reference | Treatment | Total N | Median survival (month) | P-value |
|---|---|---|---|---|
| Bramhall SR, BJC 2002 85 | Gemcitabine +/− Marimastat | 239 | 5.4 versus 5.5 | 0.95 |
| Berlin JD, JCO 2002 86 | Gemcitabine +/− 5-FU | 322 | 5.7 versus 6.5 | 0.09 |
| Colucci G, Cancer 2002 87 | Gem versus Gem + Cisplatin | 107 | 5 versus 7.5 | 0.43 |
| Rocha Lima CM, JCO 2004 88 | Gemcitabine +/− Irinotecan | 342 | 6.3 versus 6.6 | 0.78 |
| Van Custem E, JCO 2004 89 | Gemcitabine +/− Tipifarnib | 688 | 6.1 versus 6.4 | 0.75 |
| Louvet C, JCO 2005 90 | Gemcitabine +/− Oxaliplatin | 313 | 7.1 versus 9 | 0.13 |
| Oettle H, Ann Oncol 2005 91 | Gemcitabine +/− Premetexed | 565 | 6.3 versus 6.2 | 0.84 |
| Abou-Alfa GK, JCO 2006 92 | Gemcitabine +/− Exatecan | 349 | 6.2 versus 6.7 | 0.52 |
| Heinemann V, JCO 2006 93 | Gem versus Gem+Cisplatin | 195 | 6 versus 7 | 0.15 |
| Stathopoulous GP, BJC 2006 94 | Gemcitabine +/− Irinotecan | 145 | 6.4 versus 6.5 | 0.97 |
| Herrmann R, JCO 2007 95 | Gemcitabine +/− Capecitabine | 319 | 7.2 versus 8.4 | 0.23 |
| Moore MJ, JCO 2007 96 | Gemcitabine +/− Erlotinib | 569 | 5.9 versus 6.3 | 0.03 |
| Poplin E, JCO 2009 97 | Gemcitabine versus fixed dose rate Gemcitabine versus Gemcitabine + Oxaliplatin | 832 | 4.9 versus 6 versus 5.7 | 0.04 |
| 0.22 | ||||
| Van Custem E, JCO 2009 98 | Gemcitabine+Erlotinib +/− Bevacizumab | 301 | 6.0 versus 7.1 | 0.20 |
| Kindler HL, JCO 2010 99 | Gemcitabine +/− Bevacizumab | 602 | 5.9 versus 5.8 | 0.95 |
| Philip PA, JCO 2010 100 | Gemcitabine +/− Cetuximab | 745 | 5.9 versus 6.3 | 0.23 |
| Conroy T, NEJM 2011 24 | Gemcitabine versus FOLFIRINOX | 342 | 6.8 versus 11.1 | <0.001 |
| Von Hoff, NEJM 2013 101 | Gemcitabine +/− nab-paclitaxel | 861 | 8.5 versus 6.7 | P < 0.001 |
5-FU, 5-fluorouracil; +/−, one arm with and one arm without the drug following the sign.
Bold indicates statistically significant.